- Oil Prices decline the most since 1991
- The US Indices suffered another weekly loss despite the emergency intervention of the central bank
- Huge risk-off move stir financial markets
Global equities traded significantly lower last week as the fast-spreading anxiety regarding coronavirus negatively affected financial markets despite significant actions taken by central banks. Today panic is visible both Asia and Europe as all major global indexes are sinking due to a recent decision by Saudi Arabia regarding restrictions on oil production. US equities are also trading lower during today’s open due to ongoing negative sentiment. Taking into consideration the fact that the number of infected cases is still increasing we can expect higher market volatility in the week ahead. With that in mind, US indices might sharply react to any further steps taken by central banks.
Also, good data from China can have a positive impact on the markets, as the country looks to return to work following the initial outbreak and quarantine.
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile appConsidered as safe heaven US Dollar went down against the Euro and Japanese Yen while advanced against the more risky Australian and New Zealand Dollars. Emergency interest rate cuts from the Federal Reserve and Bank of Canada failed to calm investors nerves.
US500 went down today following footsteps of other global equity markets. The index is testing price zone at 2811 pts after opening of today’s cash session. If this level holds then we might expect some stabilization. However if the market makes a move below the 2811 pts swing level then the next support level can be found at 2777 pts. Source: xStation5
Tegna (TEGNA.US) shares prices went up 11% in extended trading after gaining 26% during the previous trading session based on speculations that Apollo Global submitted a $20/share all-cash bid. TEGNA has not officially confirmed these news, refusing to comment.
TEGNA (TEGNA.US) - share price is in the middle of the range between $13.18 and $18.17. Any further statements regarding the offer issued by TEGNA’s management may lead to further price movements. Source xStation5
Share prices of OPKO Health (OPK.US) one of the largest clinical labs groups in the US involved in research and commercialization pharmaceutical products, vaccines and diagnostic products gained 13% in post trading session.
OPKO Health (OPK.US) share price is testing the upper limit of the range at $2.52 per share. If the upside bias continue then the next potential level of resistance is located at $3.97 per share. Source xStation5
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
